EN DE

SINGAPORE PAINCARE HOLDINGS LIMITED (FRQ) Fair Value & Analysis

Healthcare · SG · Market cap 10.3M SGD

SP SINGAPORE PAINCARE HOLDINGS LIMITED FRQ · SG
Price0.0740 SGD
Fair Value0.0710 SGD
Upside-4.1%
Quality59/100
Watch SINGAPORE PAINCARE HOLDINGS LIMITED for free, get notified when fair value or trend changes. Watch for free
Mixed Growth
Loss-making · -18.4% net margin
Low debt · generates free cash flow
Mixed vs. peers (5/12)
Narrow moat 16/100
Evidence: Medium Range 0.0553 SGD – 0.0817 SGD Share as image

Fair value as of: Aug 13, 2026

From 13 valuation models · updated 4 days ago

Fair value updated Aug 13, 2026, revised from 0.0709 SGD to 0.0710 SGD (+0.1%) since Aug 9, 2026. Share price +15.6% over the past month.

A solid business, currently priced close to our fair value.

What matters now

  • The price sits close to our fair value, market and models broadly agree here, little valuation tension.
  • Our model range runs from 0.0553 SGD (bear) to 0.0817 SGD (bull), base 0.0710 SGD. The closer the price sits to the lower half, the larger the margin of safety.
  • Quality 59/100 (solid quality) with medium evidence: read the verdict with care.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

0.2309 SGD 0.0600 SGD Fair Value 0.0710 SGD Apr 2021 Aug 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Aug 13, 2026.

How to read this chart

60‑month range 0.0600 SGD – 0.2309 SGD · fair‑value band 0.0553 SGD – 0.0817 SGD · the 0.0740 SGD price screens above the 0.0710 SGD fair value. Dashed = 300-day average. As of Aug 13, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

SINGAPORE PAINCARE HOLDINGS LIMITED (FRQ) currently trades at 0.0740 SGD, while our model-based Fair Value estimate is 0.0710 SGD, implying the stock looks roughly 4.1% fairly valued today. The Quality Score stands at 59/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: medium).

Over the trailing twelve months, SINGAPORE PAINCARE HOLDINGS LIMITED generated revenue of 26.6M SGD at a net margin of -18.4%. Revenue declined 2.9% year over year. It earns a return on equity of -21.8%. Fundamentals as of Aug 13, 2026

Our scenario range runs from 0.0553 SGD (bear case) to 0.0817 SGD (bull case); at 0.0740 SGD, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 54% below its 52-week high and 23% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -14% fair-value upside, at -4%, FRQ screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
Growth DCF 0.1000 SGD 0.1400 SGD 0.2000 SGD 80
Rev-Margin DCF 0.2400 SGD 0.4400 SGD 0.8600 SGD 74
ROIC Compounder 0.2100 SGD 0.2900 SGD 0.3500 SGD 72
All 13 models by family
DCF Models
FCF DCF 0.1000 SGD 0.1300 SGD 0.2100 SGD 38
5Y Revenue Exit 0.2200 SGD 0.3900 SGD 0.7500 SGD 39
5Y EBITDA Exit 0.3400 SGD 0.6300 SGD 1.19 SGD 41
10Y Revenue Exit 0.1700 SGD 0.3900 SGD 0.5500 SGD 36
10Y EBITDA Exit 0.2500 SGD 0.6100 SGD 1.25 SGD 37
Earnings-Based
EPV 0.1800 SGD 0.2000 SGD 0.2100 SGD 59
Multiples
EV/EBIT 0.3700 SGD 0.4800 SGD 0.5900 SGD 53
EV/EBITDA 0.4700 SGD 0.6100 SGD 0.7600 SGD 54
EV/Revenue 0.2700 SGD 0.3700 SGD 0.4700 SGD 43
Asset-Based
NCAV (Graham) 0.0500 SGD 0.0700 SGD 0.1100 SGD 50
Growth DCF
Growth DCF 0.1000 SGD 0.1400 SGD 0.2000 SGD 80
Rev-Margin DCF 0.2400 SGD 0.4400 SGD 0.8600 SGD 74
Economic Profit
ROIC Compounder 0.2100 SGD 0.2900 SGD 0.3500 SGD 72

Widest divergence: Multiples (0.4800 SGD) versus Asset-Based (0.0700 SGD). Highest evidence: Growth DCF (80).

Notify me when FRQ reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) 26.6M SGD
Revenue growth (YoY) -2.9%
Net margin -18.4%
Return on equity -21.8%
Free cash flow 965K SGD FY2025
Operating margin 1.8%
More key figures
EPS (TTM) -0.0300 SGD
EPS growth (YoY) -54.1%

Figures from reported company fundamentals · as of Aug 13, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 59/100

Of which business quality 58 · Market factors (momentum, volatility) 26

Profitability 31
Margins and returns on capital today
Quality Growth 64
Are margins and returns improving?
Cashflow 26
Earnings quality: real cash, not paper profit
Fin. Strength 74
Balance sheet, leverage, solvency risk
Investment 94
Disciplined investing over empire-building
Low Volatility 68
Calm price path (market factor)
Momentum 10
Price trend over the last 3–12 months (market factor)
52W Momentum 7
Distance to the 52-week high (market factor)
Net Issuance 90
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Singapore Paincare Holdings Limited, an investment holding company, operates medical clinics in Singapore. It operates general practitioner clinics, specialist clinics, traditional Chinese medicine centers, and physiotherapy centers for pain screening and treatments, cancer pain therapy, pharmacotherapy, and cognitive behavioral therapy.

Full company description

Singapore Paincare Holdings Limited, an investment holding company, operates medical clinics in Singapore. It operates general practitioner clinics, specialist clinics, traditional Chinese medicine centers, and physiotherapy centers for pain screening and treatments, cancer pain therapy, pharmacotherapy, and cognitive behavioral therapy. The company was founded in 2007 and is based in Singapore.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2020 – FY2025 · reported fiscal years

SINGAPORE PAINCARE HOLDINGS LIMITED reported revenue of 26.9M SGD in FY2024 versus 9.6M SGD in FY2020, a compound +29.2%/yr. Reported net income was −4.0M SGD in FY2025.

Growth Quality 54/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2024)
26.9M SGD
Latest YoY
+21.9%
Avg. growth/yr (3Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+34.9%
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+47.2%
Revenue +29.2%/yr
FY20 9.6M SGD
FY21 11.0M SGD
FY22 18.8M SGD
FY23 22.1M SGD
FY24 26.9M SGD
Net income
FY21 2.2M SGD
FY22 3.9M SGD
FY23 −502K SGD
FY24 2.0M SGD
FY25 −4.0M SGD

Watch FRQ: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "SINGAPORE PAINCARE HOLDINGS LIMITED Fair Value". https://www.fairvalue-calculator.com/stock/FRQ

Peer Group

Medical Care Facilities · 267 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 59 · Above median
Fair Value upside −5% · Below median
Return on assets -1% · Bottom 25%
Net margin (TTM) -18% · Bottom 25%
Operating margin (TTM) 2% · Bottom 25%
Revenue growth -3% · Bottom 25%
Dividend yield (TTM) 5.8% · Top 25%
Debt / equity 0.03× · Lower than median

Valuation Multiples vs Medical Care Facilities median · lower = cheaper

P/B 0.43× · Cheaper than 75% of peers
P/S (TTM) 0.30× · Cheaper than 75% of peers
P/FCF 8.3× · Pricier than median

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 26 · sector 27
FUTURE 0 · sector 23
PAST 0 · sector 29
HEALTH 98 · sector 90
DIVIDEND 100 · sector 41

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Aug 13, 2026).

Compare SINGAPORE PAINCARE HOLDINGS LIMITED with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is SINGAPORE PAINCARE HOLDINGS LIMITED (FRQ) overvalued or undervalued?
As of Aug 13, 2026, our model estimates a fair value of 0.0710 SGD versus a price of 0.0740 SGD, about −4% (fairly valued).
What is the fair value of FRQ?
Our model-based fair value for SINGAPORE PAINCARE HOLDINGS LIMITED is 0.0710 SGD (as of Aug 13, 2026), built from audited fundamentals. The current price is 0.0740 SGD.
What is the quality score of FRQ?
SINGAPORE PAINCARE HOLDINGS LIMITED has a Quality Score of 59/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of SINGAPORE PAINCARE HOLDINGS LIMITED (FRQ)?
SINGAPORE PAINCARE HOLDINGS LIMITED reported trailing-twelve-month revenue of about 26.6M SGD (latest available figure, as of Aug 13, 2026).
What is the net profit margin of FRQ?
The net profit margin of SINGAPORE PAINCARE HOLDINGS LIMITED is about -18.4%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track SINGAPORE PAINCARE HOLDINGS LIMITED and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.